CSL moves Horizon 2 plasma technology into clinical trials
CSL Limited announced on 29 July 2026 that it will undertake clinical trial work to confirm the efficacy and safety of immunoglobulin manufactured using its next-generation Horizon 2 process.
Horizon 2 is described by the company as a patented, yield-enhancing technology that enables significantly greater production of immunoglobulin from the same base amount of plasma. The clinical work follows engagements with the U.S. Food & Drug Administration (FDA) and European Medicines Agency (EMA), and is intended to provide the clinical evidence needed to support and finalise the regulatory approval processes for the technology.
Clinical activities are expected to commence in mid-2027, using material manufactured at CSL’s Broadmeadows facility. The announcement does not disclose the size of the yield uplift, the duration of the trial, or the cost involved.
When big ASX news breaks, our subscribers know first
What Horizon 2 means and why yield matters
A technology that produces significantly greater output of immunoglobulin from the same base amount of plasma improves production without requiring proportionally more of that input, positioning it as an operational efficiency lever for the business.
CSL noted that its advanced manufacturing processes sit among several initiatives it continues to progress as part of an overall focus on operational efficiencies.
CSL’s operational efficiency programme is targeting $500-$550 million in annualised savings by FY28, making yield-enhancing manufacturing advances like Horizon 2 central to the company’s financial recovery thesis rather than merely incremental improvements.
Key points for investors to note:
-
Same plasma input, greater immunoglobulin output
-
Patented process, offering competitive protection
-
Regulatory pathway already engaged with the FDA and EMA
-
Part of CSL’s broader efficiency drive
Timeline and parallel path with Kankakee expansion
The clinical trial work will run in parallel with construction of the previously announced expansion of its Kankakee, Illinois manufacturing facility.
Clinical activities are expected to begin in mid-2027, drawing on material manufactured at the Broadmeadows facility. CSL has not yet disclosed the duration of the trial work or the precise regulatory approval timeline, stating that further information will be provided to investors when available.
| Milestone | Detail | Status |
|---|---|---|
| Regulatory engagement | FDA & EMA discussions completed | Done |
| Clinical trial commencement | Broadmeadows-manufactured material | Expected mid-2027 |
| Kankakee facility expansion | Runs in parallel with trials | Previously announced |
The investment takeaway for CSL shareholders
If regulatory approval is secured, Horizon 2 has the potential to act as a structural efficiency enhancer for CSL’s core plasma business, lifting immunoglobulin output without a proportional increase in plasma input.
In the near term, the market awaits further detail on the trial duration and the impact on the approval process, positioning these disclosures as the next catalyst to watch.
Investors exploring the broader pipeline of value-creation moves CSL is pursuing alongside its manufacturing transformation will find our deep-dive into CSL’s clazakizumab licensing deal useful; it details how the $100 million upfront payment from Eli Lilly and the non-dilutive deal structure provide capital headroom without requiring new equity issuance.
From the announcement
“Horizon 2 is a patented, yield-enhancing technology that enables significantly greater production of immunoglobulin from the same base amount of plasma.”
Don’t Miss the Next Healthcare Breakthrough
Big News Blast delivers FREE breaking ASX healthcare news directly to your inbox within minutes of release, complete with in-depth analysis already done for you. Over 20,000+ investors rely on it to stay ahead of market-moving announcements. Click the “Free Alerts” button to start receiving real-time alerts the moment the next major healthcare update drops.